Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
about
An update of current treatments for adult acute myeloid leukemiaMolecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid LeukemiaTargeting acute myeloid leukemia with TP53-independent vosaroxin.Emerging therapies for acute myeloid leukemia.RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.Therapies for acute myeloid leukemia: vosaroxin.Practical characteristics of adaptive design in phase 2 and 3 clinical trials.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Emerging therapeutic drugs for AML.Acute myeloid leukemia in the elderly: therapeutic options and choice.Emerging strategies for the treatment of older patients with acute myeloid leukemia.The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.Acute myeloid leukaemia.Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
P2860
Q26776396-5608CCD7-CDEC-4EA2-9684-4CDFF3146805Q28072058-3B619E03-E6D8-4C1F-82E0-3E2C3B59A603Q30245472-162F3676-A17C-486D-B6A7-565C280F318DQ33576363-EC7FDEDB-994E-4458-8C75-784A6DE4665BQ33759034-2332A045-85C3-4453-A006-C146FF5F2EBFQ36157664-EDE98DA8-63CB-4EB4-AB58-661C370BB52FQ38598953-14E92041-B154-44B3-BC8E-D83320E34B5AQ38603746-09225893-0EC5-40DE-8C9D-580C3B9F7DFDQ38644941-80B1AFB0-FCFD-4365-BF60-CAA01610FF1AQ38667491-095C5763-3F1A-4672-B694-19B6A7C11E23Q38675781-A1B228CE-E712-4E5A-A387-C16BE4681839Q38818726-1A522465-2EB2-4E9D-BBE3-5C3CA19F1CEDQ38829544-7B2770C4-DBD5-49F0-A8F2-F55EC959C361Q39175665-5E61B092-0A64-470F-996F-806692EE0C11Q39306416-D9F5F239-7B62-434E-8B28-88C10E720DDFQ40548451-25892E73-E752-446F-8665-324035441B4AQ47432401-EE243DA5-AC0F-49BD-A815-FED2B1EDC1F9Q48305735-219ED55C-E364-47F7-968D-17E85345CCDB
P2860
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Vosaroxin and vosaroxin plus l ...... s with acute myeloid leukemia.
@ast
Vosaroxin and vosaroxin plus l ...... s with acute myeloid leukemia.
@en
type
label
Vosaroxin and vosaroxin plus l ...... s with acute myeloid leukemia.
@ast
Vosaroxin and vosaroxin plus l ...... s with acute myeloid leukemia.
@en
prefLabel
Vosaroxin and vosaroxin plus l ...... s with acute myeloid leukemia.
@ast
Vosaroxin and vosaroxin plus l ...... s with acute myeloid leukemia.
@en
P2093
P2860
P1433
P1476
Vosaroxin and vosaroxin plus l ...... ts with acute myeloid leukemia
@en
P2093
Alan K Burnett
Claire Hemmaway
Don Milligan
Helen Dignum
Ian F Thomas
Lars Kjeldsen
Mary-Frances McMullin
Mike Dennis
Nicki Panoskaltsis
Nigel Russell
P2860
P304
P356
10.1182/BLOOD-2014-10-608117
P407
P577
2015-03-24T00:00:00Z